XAIR / Beyond Air, Inc. - Документы SEC, Годовой отчет, Доверенное заявление

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 12, 2025 Beyond Air, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 12, 2025 Beyond Air, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38892 47-3812456 (State or Other Jurisdiction of Incorporation) (Commission File Numbe

Increased revenues by 157% to $1.8 million, compared with $0.7 million for the fiscal quarter ended June 30, 2024 Awarded a national group purchasing agreement for therapeutic gases by Premier, Inc., which has more than 4,350 member hospitals and hea

Exhibit 99.1 Beyond Air® Reports Fiscal First Quarter 2026 Financial Results and Provides Corporate Update August 12, 2025 Increased revenues by 157% to $1.8 million, compared with $0.7 million for the fiscal quarter ended June 30, 2024 Awarded a national group purchasing agreement for therapeutic gases by Premier, Inc., which has more than 4,350 member hospitals and health systems in its network

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 ☐ TRANSITION REPORT PURSUANT TO S

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38892 BEYOND AIR, INC. (Exa

Form of Certificate of Amendment

Exhibit 3.1 THIRD CERTIFICATE OF AMENDMENT OF THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF BEYOND AIR, INC. Beyond Air, Inc. (the “Corporation”), a corporation organized and existing under the laws of the State of Delaware hereby certifies as follows: 1. The name of the Corporation is Beyond Air, Inc. The Corporation’s original Certificate of Incorporation was filed with the Secretary

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 9, 2025 Beyond Air, Inc. (Ex

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 9, 2025 Beyond Air, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38892 47-3812456 (State or Other Jurisdiction of Incorporation) (Commission File Number)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 20, 2025 Beyond Air, Inc. (E

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 20, 2025 Beyond Air, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38892 47-3812456 (State or Other Jurisdiction of Incorporation) (Commission File Number)

List of subsidiaries of Beyond Air, Inc.

Exhibit 21.1 Subsidiary Jurisdiction of Incorporation Beyond Air Ltd. Israel Beyond Air Ireland Limited Ireland Beyond Air Australia Pty. Ltd. Australia Beyond Cancer Bermuda Limited Bermuda Beyond Cancer U.S., Inc. Delaware NeuroNos Limited Ireland NeuroNos Israel Limited Israel XAIR Israel Ltd Israel Beyond Air Cyprus Limited Cyprus NeuroNos US Inc Delaware

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED MARCH 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-38892 BEYOND AIR, INC.

Beyond Air, Inc. Incentive Compensation Recovery Policy, effective October 2, 2023, filed as Exhibit 97 to our Annual Report on Form 10-K, as filed with the SEC on June 24, 2024, and incorporated herein by reference

Exhibit 97 Beyond Air, Inc. Incentive Compensation Recovery Policy Adopted by the Board of Directors (the “Board”) of Beyond Air, Inc. (the “Company”) on November 20, 2023 The Company is committed to conducting business in accordance with the highest ethical and legal standards, and the Board believes that a culture that emphasizes integrity and accountability is in the best interests of the Compa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 18, 2025 Beyond Air, Inc. (E

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 18, 2025 Beyond Air, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38892 47-3812456 (State or Other Jurisdiction of Incorporation) (Commission File Number)

Beyond Air Submits FDA PMA Supplement for Next Generation LungFit® PH LungFit PH II’s smaller, lightweight, transport-ready design is expected to open the entirety of the NO market Final design based upon substantial feedback from respiratory therapi

Exhibit 99.2 Beyond Air Submits FDA PMA Supplement for Next Generation LungFit® PH LungFit PH II’s smaller, lightweight, transport-ready design is expected to open the entirety of the NO market Final design based upon substantial feedback from respiratory therapists across the country Garden City, NY, June 16, 2025 – Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial sta

Beyond Air® Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update Revenues increased 220% to $3.7 million, compared with $1.2 million for the fiscal year ended March 31, 2024 Expect to report revenue of at least $1

Exhibit 99.1 Beyond Air® Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update Revenues increased 220% to $3.7 million, compared with $1.2 million for the fiscal year ended March 31, 2024 Expect to report revenue of at least $1.7 million for quarter ending June 30, 2025, and introducing revenue guidance of $12-$16 million for the full fiscal year 2026 Submitted

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State

First-in-human studies anticipated to begin in 2026 Engaged a top tier U.S. based contract manufacturer to ensure the highest standards of quality Currently in the advanced stages of formulation development for subcutaneous injection, with plans for

Exhibit 99.1 NeuroNOS Secures $2.0 Million in Funding to Advance Development of an Innovative Autism Therapy First-in-human studies anticipated to begin in 2026 Engaged a top tier U.S. based contract manufacturer to ensure the highest standards of quality Currently in the advanced stages of formulation development for subcutaneous injection, with plans for an oral formulation BOSTON, March 24, 202

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 24, 2025 Beyond Air, Inc. (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 24, 2025 Beyond Air, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38892 47-3812456 (State or Other Jurisdiction of Incorporation) (Commission File Number

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 11, 2025 Beyond Air, Inc. (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 11, 2025 Beyond Air, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38892 47-3812456 (State or Other Jurisdiction of Incorporation) (Commission File Number

Beyond Air Announces Agreements Expanding Global Distribution of LungFit® PH Distribution agreements recently signed for France, Turkey, Romania and Morocco LungFit PH international distribution network now includes 18 countries Initial international

Exhibit 99.1 Beyond Air Announces Agreements Expanding Global Distribution of LungFit® PH Distribution agreements recently signed for France, Turkey, Romania and Morocco LungFit PH international distribution network now includes 18 countries Initial international orders for LungFit PH systems have been received for four countries GARDEN CITY, N.Y., March 11, 2025 (GLOBE NEWSWIRE) — Beyond Air, Inc

At-The-Market Equity Offering Sales Agreement, dated as of February 14, 2025

Exhibit 1.1 Beyond Air, Inc. Up to $35,000,000 COMMON STOCK AT-THE-MARKET SALES AGREEMENT February 14, 2025 BTIG, LLC 65 East 55th Street New York, New York 10022 Ladies and Gentlemen: Beyond Air, Inc., a Delaware corporation (the “Company”), and BTIG, LLC (the “Agent”), as sales agent, confirm their agreement (this “Agreement”) as follows: 1. Issuance and Sale of Shares. The Company agrees that,

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 14, 2025 Beyond Air, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38892 47-3812456 (State or other jurisdiction of incorporation) (Commission File

Results of Operations and Financial Condition, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 10, 2025 Beyond Air, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38892 47-3812456 (State or Other Jurisdiction of Incorporation) (Commission File Num

Beyond Air, Inc. Common Stock

Filed Pursuant to Rule 424(b)(5) Registration No. 333-284653 PROSPECTUS SUPPLEMENT (To Prospectus dated February 10, 2025) $9,892,518 Beyond Air, Inc. Common Stock We have entered into a sales agreement with BTIG, LLC, or BTIG, who we refer to as the agent, relating to shares of our common stock offered by this prospectus supplement. In accordance with the terms of the sales agreement, we may offe

Beyond Air® Reports Fiscal Third Quarter 2025 Financial Results and Provides Corporate Update Revenues increased 34% compared to the previous quarter ended September 30, 2024; and exceeded $1 million Received CE Mark for LungFit PH® in Europe and Mar

Exhibit 99.1 Beyond Air® Reports Fiscal Third Quarter 2025 Financial Results and Provides Corporate Update Revenues increased 34% compared to the previous quarter ended September 30, 2024; and exceeded $1 million Received CE Mark for LungFit PH® in Europe and Market Authorization in Australia; international shipments to commence later this year Conference call at 4:30 p.m. ET today, February 10th

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38892 BEYOND AIR, INC.

BEYOND AIR, INC. 900 Stewart Avenue, Suite 301 Garden City, NY 11530

BEYOND AIR, INC. 900 Stewart Avenue, Suite 301 Garden City, NY 11530 February 6, 2025 VIA EDGAR Securities and Exchange Commission Division of Corporate Finance 100 F. Street, N.E. Washington, D.C. 20549 Re: Beyond Air, Inc. Registration Statement on Form S-3 Filed January 31, 2025 File No. 333-284653 Ladies and Gentlemen: In accordance with Rule 461 under the Securities Act of 1933, as amended, t

Beyond Air® Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement

Exhibit 99.1 Beyond Air® Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement Garden City, NY, February 5, 2025 – Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced it received a notific

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 5, 2025 Beyond Air, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38892 47-3812456 (State or Other Jurisdiction of Incorporation) (Commission File Numb

As filed with the Securities and Exchange Commission on January 31, 2025

As filed with the Securities and Exchange Commission on January 31, 2025 Registration No.

Form of Indenture (filed herewith).

Exhibit 4.4 BEYOND AIR, INC. and as Trustee INDENTURE Dated as of ARTICLE 1 DEFINITIONS AND INCORPORATION BY REFERENCE 1 1.1 Definitions 1 1.2 Other Definitions 4 1.3 Incorporation by Reference of Trust Indenture Act 4 1.4 Rules of Construction 5 ARTICLE 2 THE SECURITIES 5 2.1 Issuable in Series 5 2.2 Establishment of Terms of Series of Securities 5 2.3 Execution and Authentication 7 2.4 Registrar

Filing Fee Table (filed herewith).

Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Beyond Air, Inc.

Letter from Marcum LLP to the Securities and Exchange Commission, dated December 20, 2024.

Exhibit 16.1 December 20, 2024 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Commissioners: We have read the statements made by Beyond Air, Inc. under Item 4.01 of its Form 8-K dated December 17, 2024. We agree with the statements concerning our Firm in such Form 8-K; we are not in a position to agree or disagree with other statements of Beyond Air, Inc. contained ther

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 17, 2024 Beyond Air, Inc

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 17, 2024 Beyond Air, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38892 47-3812456 (State or Other Jurisdiction of Incorporation) (Commission File Num

As filed with the Securities and Exchange Commission on December 13, 2024

As filed with the Securities and Exchange Commission on December 13, 2024 Registration No.

Filing Fee Table.

Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Beyond Air, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Proposed Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, par value

Form of Stock Option Agreement (Inducement Grant).

Exhibit 10.2 Stock Option Inducement Agreement This Stock Option Inducement Agreement (this “Agreement”) is made and entered into as of [DATE] by and between BEYOND AIR, INC., a Delaware corporation (the “Company”) and [NAME] (the “Participant”). Grant Date: Exercise Price per Share: Number of Option Shares: Expiration Date: 1. Grant of Option. 1.1 Grant; Type of Option. The Company desires to emp

Beyond Air, Inc. Seventh Amended and Restated 2013 Equity Incentive Plan.

Exhibit 10.1 BEYOND AIR, INC. Seventh AMENDED AND RESTATED 2013 EQUITY INCENTIVE PLAN (effective November 22, 2024, subject to stockholder approval) 1. Purpose; Eligibility. 1.1 General Purpose. This Beyond Air, Inc. Seventh Amended and Restated 2013 Equity Incentive Plan (the “Plan”) is hereby established by Beyond Air, Inc., a Delaware corporation (the “Company”), which amends and restates the S

Beyond Cancer Announces Approval by the Israeli Ministry of Health to Conduct a Phase 1b Clinical Trial Utilizing Low Volume Ultra-High Concentration Nitric Oxide (LV UNO) in Combination with Anti-PD-1 Therapy - The Phase 1b study will evaluate LV UN

Exhibit 99.1 Beyond Cancer Announces Approval by the Israeli Ministry of Health to Conduct a Phase 1b Clinical Trial Utilizing Low Volume Ultra-High Concentration Nitric Oxide (LV UNO) in Combination with Anti-PD-1 Therapy - The Phase 1b study will evaluate LV UNO in unresectable cutaneous or subcutaneous histologically confirmed primary or metastatic solid tumor cancer patients that have progress

Other Events, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 3, 2024 Beyond Air, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38892 47-3812456 (State or Other Jurisdiction of Incorporation) (Commission File Numb

Other Events, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 2, 2024 Beyond Air, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38892 47-3812456 (State or Other Jurisdiction of Incorporation) (Commission File Numb

Beyond Air Receives CE Mark in Europe for the LungFit® PH System Indication covers newborn infants with hypoxic respiratory failure and peri- and post-operative pulmonary hypertension to improve right ventricular function in conjunction with heart su

Exhibit 99.1 Beyond Air Receives CE Mark in Europe for the LungFit® PH System Indication covers newborn infants with hypoxic respiratory failure and peri- and post-operative pulmonary hypertension to improve right ventricular function in conjunction with heart surgery A $1 million milestone payment is triggered from Asia-Pacific partner, Getz Healthcare Garden City, NY, December 2, 2024 – Beyond A

Second Certificate of Amendment of Amended and Restated Certificate of Incorporation, dated November 22, 2024 (incorporated herein by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed with the Commission on November 26, 2024).

Exhibit 3.1 SECOND CERTIFICATE OF AMENDMENT SECOND CERTIFICATE OF AMENDMENT OF THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF BEYOND AIR, INC. Beyond Air, Inc. (the “Corporation”), a corporation organized and existing under the laws of the State of Delaware hereby certifies as follows: 1. The name of the Corporation is Beyond Air, Inc. The Corporation’s original Certificate of Incorporat

Submission of Matters to a Vote of Security Holders, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 22, 2024 Beyond Air, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38892 47-3812456 (State or Other Jurisdiction of Incorporation) (Commission File Num

73,765,634 Shares of Common Stock

Filed pursuant to Rule 424(b)(3) Registration No. 333-282834 PROSPECTUS 73,765,634 Shares of Common Stock The selling stockholders named in this prospectus may use this prospectus to offer and resell from time to time up to an aggregate of 73,765,634 shares of our common stock, par value $0.0001 per share, which are comprised of (i) 22,046,747 shares of common stock issued and outstanding (“common

BEYOND AIR, INC. 900 Stewart Avenue, Suite 301 Garden City, NY 11530

BEYOND AIR, INC. 900 Stewart Avenue, Suite 301 Garden City, NY 11530 November 22, 2024 VIA EDGAR Securities and Exchange Commission Division of Corporate Finance 100 F. Street, N.E. Washington, D.C. 20549 Attention: Juan Grana and Katherine Bagley Re: Beyond Air, Inc. Registration Statement on Form S-3 File No. 333-282834 Ladies and Gentlemen: In accordance with Rule 461 under the Securities Act o

Filing Fee Table (filed herewith).

Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Beyond Air, Inc.

As filed with the Securities and Exchange Commission on November 21, 2024

As filed with the Securities and Exchange Commission on November 21, 2024 Registration Statement No.

Results of Operations and Financial Condition, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 11, 2024 Beyond Air, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38892 47-3812456 (State or Other Jurisdiction of Incorporation) (Commission File Num

Beyond Air® Reports Fiscal Second Quarter 2025 Financial Results and Provides Corporate Update Revenues increased 17% compared to the previous quarter ended June 30, 2024 Strengthened balance sheet is expected to provide sufficient cash runway throug

Exhibit 99.1 Beyond Air® Reports Fiscal Second Quarter 2025 Financial Results and Provides Corporate Update Revenues increased 17% compared to the previous quarter ended June 30, 2024 Strengthened balance sheet is expected to provide sufficient cash runway through June 2026 Completed a $20.6 million private placement offering with multiple healthcare-focused institutional funds and Company insider

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38892 BEYOND AIR, INC.

1185 AVENUE OF THE AMERICAS | 31ST FLOOR | NEW YORK, NY | 10036 T (212) 930-9700 | F (212) 930-9725 | WWW.SRFC.LAW

November 8, 2024 VIA EDGAR Juan Grana and Katherine Bagley Division of Corporation Finance Office of Industrial Applications and Services Securities and Exchange Commission 100 F Street, NE Washington, D.

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 1, 2024 Beyond Air, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38892 47-3812456 (State or Other Jurisdiction of Incorporation) (Commission File Numb

Form of Common Stock Purchase Warrant filed as Exhibit 4.1 to our Current Report on Form 8-K, filed with the SEC on November 6, 2024, and incorporated herein by reference.

Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES OR IN ANY OTHER JURISDICTION. NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE MAY BE OFFERED, SOLD OR TRANSFERRED IN THE ABSENCE OF AN EFFECTIVE REGISTR

Loan and Security Agreement

Exhibit 10.1 LOAN AND SECURITY AGREEMENT This LOAN AND SECURITY AGREEMENT (“Agreement”) is entered into as of November 1, 2024 but effective as of October 4, 2024, among Beyond Air, Inc., a Delaware corporation (the “Borrower”), BCR8V LLC, a Delaware limited liability company (“Lender”). PRELIMINARY STATEMENTS The Borrower has requested that Lender extend a $11,500,000 term loan to the Borrower. L

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State

As filed with the Securities and Exchange Commission on October 25, 2024

As filed with the Securities and Exchange Commission on October 25, 2024 Registration Statement No.

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Beyond Air, Inc.

900 STEWART AVENUE, Suite 301 Garden City, NY 11530 NOTICE OF ANNUAL MEETING OF STOCKHOLDERS To Be Held at 4:30 p.m. Eastern Time on Friday, November 22, 2024

900 STEWART AVENUE, Suite 301 Garden City, NY 11530 NOTICE OF ANNUAL MEETING OF STOCKHOLDERS To Be Held at 4:30 p.

Shareholder Director Nominations

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 9, 2024 Beyond Air, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38892 47-3812456 (State or Other Jurisdiction of Incorporation) (Commission File Numbe

XAIR / Beyond Air, Inc. / Avenue Venture Opportunities Fund, L.P. - SC 13G/A Passive Investment

SC 13G/A 1 beyondairsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Act of 1934 (Amendment No. 1)* BEYOND AIR, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 08862L103 (CUSIP Number) October 4, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropria

Joint Filing Agreement dated October 3, 2024.

EX-99.2 2 beyondairex99-2.htm EXHIBIT 99.2 Exhibit 99.2 AGREEMENT JOINT FILING OF SCHEDULE 13G Each of the undersigned hereby agrees to file jointly the Schedule 13G to which this Agreement is attached, and any amendments to the Schedule 13G (the “Schedule 13G”) filed with respect to the common stock, par value $0.0001 per share, of Beyond Air, Inc., which may be deemed necessary, pursuant to Regu

XAIR / Beyond Air, Inc. / Avenue Venture Opportunities Fund, L.P. - SC 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Act of 1934 (Amendment No. )* BEYOND AIR, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 08862L103 (CUSIP Number) September 26, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant

Power of Attorney dated January 28, 2019.

EX-99.1 2 beyondairex99-1.htm EXHIBIT 99.1 Exhibit 99.1 POWER OF ATTORNEY This Power of Attorney is being granted in connection with executing regulatory filings and related documents. Marc Lasry hereby constitutes and appoints Andrew Schinder, Chief Compliance Officer, irrevocably as his true and lawful agent and attorney-in-fact (the “Attorney”), in his name, place and stead, to execute regulato

Joint Filing Agreement.

EX-99.2 3 beyondairex99-2.htm EXHIBIT 99.2 Exhibit 99.2 AGREEMENT JOINT FILING OF SCHEDULE 13G Each of the undersigned hereby agrees to file jointly the Schedule 13G to which this Agreement is attached, and any amendments to the Schedule 13G (the “Schedule 13G”) filed with respect to the common stock, par value $0.0001 per share, of Beyond Air, Inc., which may be deemed necessary, pursuant to Regu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 27, 2024 Beyond Air, In

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 27, 2024 Beyond Air, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38892 47-3812456 (State or Other Jurisdiction of Incorporation) (Commission File Nu

Form of Securities Purchase Agreement dated September 26, 2024, by and between Beyond Air, Inc. and the purchasers, filed as Exhibit 10.1 to our Current Report on Form 8-K, filed with the SEC on September 27, 2024 and incorporated herein by reference.

Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of September [ ], 2024 (the “Effective Date”), among Beyond Air, Inc., a Delaware corporation (the “Company”), and each purchaser identified on Exhibit A attached hereto (each a “Purchaser” and, collectively, the “Purchasers”). WHEREAS, the Company and the Purchasers are executing and deliv

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 26, 2024 Beyond Air, In

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 26, 2024 Beyond Air, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38892 47-3812456 (State or Other Jurisdiction of Incorporation) (Commission File Nu

Beyond Air Announces $20.6 Million Private Placement Offering Priced At-the-Market Under Nasdaq Rules – Financing strengthens balance sheet and is expected to provide sufficient cash runway through June 2026 – – Retiring $17.5 million in Avenue Capit

Exhibit 99.1 Beyond Air Announces $20.6 Million Private Placement Offering Priced At-the-Market Under Nasdaq Rules – Financing strengthens balance sheet and is expected to provide sufficient cash runway through June 2026 – – Retiring $17.5 million in Avenue Capital debt, aided by $11.5 million in new debt from insider-led group; eliminates $12 million in scheduled debt payments through June 2026 –

Engagement Letter dated August 16, 2024, by and among Beyond Air, Inc., BTIG, LLC, Laidlaw & Company (UK) LTD, Arcadia Securities, LLC, and Jones Trading Institutional Services LLC, filed as Exhibit 10.3 to our Current Report on Form 8-K, filed with the SEC on September 27, 2024 and incorporated herein by reference.

Exhibit 10.3 August 16, 2024 Strictly Confidential Steve Lisi Chief Executive Officer and Chairman of the Board Beyond Air, Inc. 900 Stewart Avenue, Suite 301 Garden City, NY 11530 Dear Steve: This letter agreement (this “Agreement”) confirms the understanding with respect to the new engagement by Beyond Air, Inc. (collectively with its subsidiaries and affiliates, the “Company”) of BTIG, LLC (“BT

Form of Pre-funded Warrant, by and between Beyond Air, Inc. and the purchasers, filed as Exhibit 4.1 to our Current Report on Form 8-K, filed with the SEC on September 27, 2024 and incorporated herein by reference.

Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES OR IN ANY OTHER JURISDICTION. NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE MAY BE OFFERED, SOLD OR TRANSFERRED IN THE ABSENCE OF AN EFFECTIVE REGISTR

Form of Common Warrant, by and between Beyond Air, Inc. and the purchasers, filed as Exhibit 4.2 to our Current Report on Form 8-K, filed with the SEC on September 27, 2024 and incorporated herein by reference.

Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES OR IN ANY OTHER JURISDICTION. NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE MAY BE OFFERED, SOLD OR TRANSFERRED IN THE ABSENCE OF AN EFFECTIVE REGISTR

Form of Registration Rights Agreement dated September 26, 2024, by and between Beyond Air, Inc. and the purchasers dated September 27, 2024, filed as Exhibit 10.2 to our Current Report on Form 8-K, filed with the SEC on September 27, 2024 and incorporated herein by reference.

Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of September [ ], 2024, by and between Beyond Air, Inc., a Delaware corporation (the “Company”), and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”). This Agreement is made pursuant to the Securities Pu

Beyond Air, Inc. 900 Stewart Avenue, Suite 301 Garden City, NY 11530 August 28, 2024

Beyond Air, Inc. 900 Stewart Avenue, Suite 301 Garden City, NY 11530 August 28, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Beyond Air, Inc. Registration Statement on Form S-3 Filed August 20, 2024 File No. 333-281667 Request for Acceleration of Effective Date Ladies and Gentlemen: Pursuant to Rule 461 of the

As filed with the Securities and Exchange Commission on August 20, 2024

As filed with the Securities and Exchange Commission on August 20, 2024 Registration Statement No.

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Beyond Air, Inc.

Results of Operations and Financial Condition, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 6, 2024 Beyond Air, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38892 47-3812456 (State or Other Jurisdiction of Incorporation) (Commission File Number

Beyond Air® Reports Fiscal First Quarter 2025 Financial Results and Provides Corporate Update Revenues increased 45% compared to the previous quarter ended March 31, 2024 Optimized LungFit PH device continues to expand footprint and strengthen custom

Exhibit 99.1 Beyond Air® Reports Fiscal First Quarter 2025 Financial Results and Provides Corporate Update Revenues increased 45% compared to the previous quarter ended March 31, 2024 Optimized LungFit PH device continues to expand footprint and strengthen customer base Amir Avniel, Beyond Air Board member and Chief Business Officer, appointed Chief Executive Officer of NeuroNOS, Beyond Air’s whol

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO S

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38892 BEYOND AIR, INC. (Exa

Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Results of Operations and Financial Condition, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 21, 2024 Beyond Air, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38892 47-3812456 (State or Other Jurisdiction of Incorporation) (Commission File Number)

First Amendment to Loan Documents, by and among Beyond Air, Inc., Beyond Air Ltd., Avenue Capital Management II, L.P., as Agent, and the Lenders party thereto, dated as of June 21, 2024, filed as Exhibit 10.1 to our Current Report on Form 8-K filed with the SEC on June 27, 2024.

Exhibit 10.1 First Amendment to Loan Documents This First Amendment to Loan Documents (this “Amendment”) is entered into as of June 21, 2024, by and among AVENUE CAPITAL MANAGEMENT II, L.P., a Delaware limited partnership (as administrative and collateral agent (in such capacity, “Agent”)), AVENUE VENTURE OPPORTUNITIES FUND, L.P., a Delaware limited partnership (“Avenue”), AVENUE VENTURE OPPORTUNI

Form of Common Stock Purchase Warrant, by and between Beyond Air, Inc. and Avenue Venture Opportunities Fund, L.P., dated as of June 21, 2024, filed as Exhibit 4.1 to our Current Report on Form 8-K, filed with the SEC on June 27, 2024 and incorporated herein by reference.

Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR

Form of Common Stock Purchase Warrant, by and between Beyond Air, Inc. and Avenue Venture Opportunities Fund II, L.P., dated as of June 21, 2024, filed as Exhibit 4.2 to our Current Report on Form 8-K, filed with the SEC on June 27, 2024 and incorporated herein by reference.

Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR

Beyond Air® Reports Fiscal Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update Appointed industry veteran, David Webster, as new Chief Commercial Officer Recently upgraded LungFit PH device expands customer base; revenue

Exhibit 99.1 Beyond Air® Reports Fiscal Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update Appointed industry veteran, David Webster, as new Chief Commercial Officer Recently upgraded LungFit PH device expands customer base; revenue growth expected to accelerate each quarter going forward FY 2025 revenue guidance revised to greater than $10 million Implemented capita

List of subsidiaries of Beyond Air, Inc.

Exhibit 21.1 Subsidiary Jurisdiction of Incorporation Beyond Air Ltd. Israel Beyond Air Ireland Limited Ireland Beyond Air Australia Pty. Ltd. Australia Beyond Cancer Bermuda Limited Bermuda Beyond Cancer U.S., Inc. Delaware NeuroNos Limited Ireland NeuroNos Israel Limited Israel XAIR Israel Ltd Israel Beyond Cancer Cyprus Limited Cyprus

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED MARCH 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-38892 BEYOND AIR, INC.

Beyond Air, Inc. [Compensation Recoupment] Policy, effective October 2, 2023

Exhibit 97 Beyond Air, Inc. Incentive Compensation Recovery Policy Adopted by the Board of Directors (the “Board”) of Beyond Air, Inc. (the “Company”) on November 20, 2023 The Company is committed to conducting business in accordance with the highest ethical and legal standards, and the Board believes that a culture that emphasizes integrity and accountability is in the best interests of the Compa

Consulting Agreement, dated as of February 14, 2024, by and between Beyond Air, Inc. and Jeff Myers.

Exhibit 10.31 CONSULTANCY AGREEMENT This Consultancy Agreement (the “Agreement”) is entered into on February , 2024, by and between Beyond Air, Inc., a company incorporated in the State of Delaware (the “Company”), and Jeff Myers, M.D., Ph.D. residing 1001 Julia Street, New Orleans, LA 70113 (the “Consultant”). WHEREAS, the Consultant serves as Chief Medical Officer under the terms set forth in hi

Beyond Air® Appoints David Webster as Chief Commercial Officer Mr. Webster brings more than 20 years of executive level experience in the life sciences industry

Exhibit 99.1 Beyond Air® Appoints David Webster as Chief Commercial Officer Mr. Webster brings more than 20 years of executive level experience in the life sciences industry GARDEN CITY, N.Y., June 13, 2024 – Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of endogenous and exogenous ni

Other Events, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 13, 2024 Beyond Air, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38892 47-3812456 (State or Other Jurisdiction of Incorporation) (Commission File Number)

Form of Common Stock Purchase Warrant, by and between Beyond Air, Inc. and the Holders party thereto, filed as Exhibit 4.1 to our Current Report on Form 8-K, filed with the SEC on March 22, 2024 and incorporated herein by reference.

Exhibit 4.1 COMMON STOCK PURCHASE WARRANT BEYOND AIR, INC. Warrant Shares: Initial Exercise Date: March 22, 2024 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exe

Beyond Air® Announces Pricing of $16.0 Million Registered Direct Offering of Common Stock and Warrants

Exhibit 99.1 Beyond Air® Announces Pricing of $16.0 Million Registered Direct Offering of Common Stock and Warrants March 20, 2024 | 9:02 am EST GARDEN CITY, N.Y., March 20, 2024 — Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of endogenous and exogenous nitric oxide (NO) to improve t

Beyond Air, Inc. 9,638,556 Shares of Common Stock Common Stock Warrants to Purchase 9,638,556 Shares of Common Stock Up to 9,638,556 Shares of Common Stock underlying such Common Stock Warrants

Filed Pursuant to Rule 424(b)(5) Registration No. 333-262311 PROSPECTUS SUPPLEMENT (To Prospectus dated February 1, 2022) Beyond Air, Inc. 9,638,556 Shares of Common Stock Common Stock Warrants to Purchase 9,638,556 Shares of Common Stock Up to 9,638,556 Shares of Common Stock underlying such Common Stock Warrants We are offering (i) 9,638,556 shares of our common stock, par value $0.001 per share

Other Events, Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 20, 2024 BEYOND AIR, INC (Exact name of registrant as specified in its charter) Delaware 001-38892 47-3812456 (State or other jurisdiction (Commission (IRS Employer of incorpora

Form of Securities Purchase Agreement dated March 20, 2024, by and among Beyond Air, Inc and the Purchasers, filed as Exhibit 10.1 to our Current Report on Form 8-K, as filed with the SEC on March 22, 2024 and incorporated herein by reference.

Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of , 2024, between Beyond Air, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions set forth in t

Form of Placement Agency Agreement, dated March 20, 2024, by and among Beyond Air, Inc. and Roth Capital Partners, LLC and Laidlaw & Company (UK) Ltd., filed as Exhibit 1.1 to our Current Report on Form 8-K, as filed with the SEC on March 22, 2024, and incorporated herein by reference.

Exhibit 1.1 PLACEMENT AGENCY AGREEMENT March 20, 2024 Roth Capital Partners, LLC 888 San Clemente Drive, Suite 400 Newport Beach, CA 92660 Laidlaw & Company (UK) Ltd. 521 Fifth Avenue, 12th Floor New York, NY 10175 Ladies and Gentlemen: Introduction. Subject to the terms and conditions herein (this “Agreement”), Beyond Air, Inc., a Delaware corporation (the “Company”), hereby agrees to sell up to

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 8, 2024 Beyond Air, Inc. (E

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 8, 2024 Beyond Air, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38892 47-3812456 (State or Other Jurisdiction of Incorporation) (Commission File Number)

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2024 Beyond Air, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-38892 47-3812456 (State or Other Jurisdiction of Incorporation) (Commission File

Up to $50,000,000 Beyond Air, Inc. Common Stock

Filed Pursuant to Rule 424(b)(5) Registration No. 333-262311 PROSPECTUS SUPPLEMENT (To Prospectus dated February 1, 2022 and Prospectus Supplement dated February 4, 2022) February 28, 2024 Up to $50,000,000 Beyond Air, Inc. Common Stock This prospectus supplement (the “Supplement”) supplements the prospectus supplement (the “Prospectus Supplement”), dated February 4, 2022, providing for the offer

Amendment No. 1 to Sales Agreement, dated February 28, 2024, by and among Beyond Air, Inc. and Truist Securities, Inc. and Oppenheimer & Co. Inc., filed as Exhibit 10.1 to our Current Report on Form 8-K, as filed with the SEC on March 1, 2024 and incorporated herein by reference.

Exhibit 10.1 AMENDMENT NO. 1 TO SALES AGREEMENT February 28, 2024 Truist Securities, Inc. 3333 Peachtree Road, 11th Floor Atlanta, Georgia 30326 Oppenheimer & Co. Inc. 85 Broad Street New York, New York 10004 Ladies and Gentlemen: Beyond Air, Inc., a Delaware corporation (the “Company”), together with Truist Securities, Inc. (“Truist”) and Oppenheimer & Co. Inc. (“Oppenheimer”), are parties to tha

Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 12, 2024 Beyond Air, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38892 47-3812456 (State or Other Jurisdiction of Incorporation) (Commission File Num

Beyond Air® Reports Financial Results for Third Quarter of Fiscal Year 2024 Commercial demand for LungFit® PH increasing; manufacturing of upgraded devices is ramping up to meet growing demand PMA supplement for the expansion of LungFit PH label to i

Exhibit 99.1 Beyond Air® Reports Financial Results for Third Quarter of Fiscal Year 2024 Commercial demand for LungFit® PH increasing; manufacturing of upgraded devices is ramping up to meet growing demand PMA supplement for the expansion of LungFit PH label to include cardiac surgery accepted for filing and under substantive review by the FDA U.S. pilot trial of LungFit® PRO to treat viral commun

XAIR / Beyond Air, Inc. / Mosseri Marlio Charles - PRIMARY DOCUMENT Passive Investment

SC 13G/A 1 charlesmosserimarlio13g-a.htm PRIMARY DOCUMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A (Amendment No. 4)* UNDER THE SECURITIES EXCHANGE ACT OF 1934 Beyond Air, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 08862L103 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38892 BEYOND AIR, INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State

Form of Stock Option Agreement (Inducement Stock Option Award).

Exhibit 10.2 Stock Option Inducement Agreement This Stock Option Inducement Agreement (this “Agreement”) is made and entered into as of [DATE] by and between BEYOND AIR, INC., a Delaware corporation (the “Company”) and [NAME] (the “Participant”). Grant Date: Exercise Price per Share: Number of Option Shares: Expiration Date: 1. Grant of Option. 1.1 Grant; Type of Option. The Company desires to emp

As filed with the Securities and Exchange Commission on December 20, 2023

As filed with the Securities and Exchange Commission on December 20, 2023 Registration No.

Filing Fee Table.

Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Beyond Air, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Proposed Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, par value

Form of Restricted Stock Unit Agreement (Inducement Restricted Stock Unit Award).

Exhibit 10.3 BEYOND AIR, INC. RESTRICTED STOCK UNIT GRANT NOTICE (INDUCEMENT AWARD) Beyond Air, Inc. (the “Company”) hereby awards to Participant a Restricted Stock Unit Award for the number of shares of the Company’s Common Stock (“Restricted Stock Units”) set forth below (the “Award”). The Restricted Stock Units are granted to the Participant in connection with the Participant’s entering into em

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 13, 2023 Beyond Air, Inc

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 13, 2023 Beyond Air, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38892 47-3812456 (State or Other Jurisdiction of Incorporation) (Commission File Num

Beyond Air® Reports Financial Results for Second Quarter of Fiscal Year 2024 Provides fiscal year 2025 revenue guidance of $12 - $16 million US pilot trial of LungFit® PRO to treat viral community acquired pneumonia (VCAP) underway with data expected

Exhibit 99.1 Beyond Air® Reports Financial Results for Second Quarter of Fiscal Year 2024 Provides fiscal year 2025 revenue guidance of $12 - $16 million US pilot trial of LungFit® PRO to treat viral community acquired pneumonia (VCAP) underway with data expected mid-calendar 2024 Beyond Cancer presents positive first-in-human data for intratumoral administration of ultra-high concentration nitric

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPORT PURSUANT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38892 BEYOND AIR, INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 7, 2023 Beyond Air, Inc

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 7, 2023 Beyond Air, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38892 47-3812456 (State or Other Jurisdiction of Incorporation) (Commission File Num

Beyond Air® and Getz Healthcare Enter Strategic Collaboration to Commercialize LungFit PH in Asia-Pacific Region Partnership provides access to hospitals in key Asia-Pacific countries Getz Healthcare will make a payment to Beyond Air upon receipt of

Exhibit 99.1 Beyond Air® and Getz Healthcare Enter Strategic Collaboration to Commercialize LungFit PH in Asia-Pacific Region Partnership provides access to hospitals in key Asia-Pacific countries Getz Healthcare will make a payment to Beyond Air upon receipt of CE Mark Beyond Air will receive royalty payments based on net sales Garden City, NY, September 7, 2023 – Beyond Air, Inc. (NASDAQ: XAIR)

Beyond Air, Inc. 900 Stewart Avenue, Suite 301 Garden City, NY 11530 August 17, 2023

Beyond Air, Inc. 900 Stewart Avenue, Suite 301 Garden City, NY 11530 August 17, 2023 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Beyond Air, Inc. Registration Statement on Form S-3 Filed August 11, 2023 File No. 333-273942 Request for Acceleration of Effective Date Ladies and Gentlemen: Pursuant to Rule 461 of the

Results of Operations and Financial Condition, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 10, 2023 Beyond Air, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38892 47-3812456 (State or Other Jurisdiction of Incorporation) (Commission File Numbe

Beyond Air® Reports Financial Results for First Quarter of Fiscal Year 2024 Reported commercial sales for LungFit® PH for the treatment of term and near-term neonates with hypoxic respiratory failure Currently have in excess of $1 million in annual c

Exhibit 99.1 Beyond Air® Reports Financial Results for First Quarter of Fiscal Year 2024 Reported commercial sales for LungFit® PH for the treatment of term and near-term neonates with hypoxic respiratory failure Currently have in excess of $1 million in annual commercial LungFit PH contracts Secured up to $40 million in debt financing from Avenue Capital Reached agreement with FDA to run a U.S. c

As filed with the Securities and Exchange Commission on August 11, 2023

As filed with the Securities and Exchange Commission on August 11, 2023 Registration Statement No.

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Beyond Air, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO S

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38892 BEYOND AIR, INC. (Exa

Results of Operations and Financial Condition, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 22, 2023 Beyond Air, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38892 47-3812456 (State or Other Jurisdiction of Incorporation) (Commission File Number)

Beyond Air® Reports Financial Results for Fourth Quarter and Fiscal Year-End 2023 Successfully completed phase 1 of U.S. commercial launch, with multiple hospitals contracted, and have initiated phase 2 of launch for LungFit® PH for the treatment of

Exhibit 99.1 Beyond Air® Reports Financial Results for Fourth Quarter and Fiscal Year-End 2023 Successfully completed phase 1 of U.S. commercial launch, with multiple hospitals contracted, and have initiated phase 2 of launch for LungFit® PH for the treatment of term and near-term neonates with hypoxic respiratory failure Presented positive preclinical data for ultra-high concentration nitric oxid

List of subsidiaries of Beyond Air, Inc.

Exhibit 21.1 Subsidiary Jurisdiction of Incorporation Beyond Air Ltd. Israel Beyond Air Ireland Limited Ireland Beyond Air Australia Pty. Ltd. Australia Beyond Cancer Bermuda Limited Bermuda Beyond Cancer U.S., Inc. Delaware XAIR Israel Ltd Israel Beyond Cancer Cyprus Limited Cyprus

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED MARCH 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-38892 BEYOND AIR, INC.

Employment Agreement, dated as of March 27, 2023, by and between Beyond Air, Inc. and Jeff Myers.

Exhibit 10.29 EMPLOYMENT AGREEMENT EMPLOYMENT AGREEMENT (“Agreement”) is effective on March 27th, 2023 between Beyond Air, Inc. (the “Company”), a Delaware Company, and Jeff L. Myers, M.D., Ph.D. (the “Employee”), residing at 1001 Julia Street, New Orleans, LA 70113. Recital: The parties desire to enter into this Agreement so as to provide for the employment of the Employee by the Company and for

Supplement to the Loan and Security Agreement, by and among Beyond Air, Inc., Avenue Capital Management II, L.P., as Agent, and the Lenders party thereto, dated as of June 15, 2023, filed as Exhibit 10.2 to our Current Report on Form 8-K, as filed with the SEC on June 20, 2023 and incorporated herein by reference.

Exhibit 10.2 SUPPLEMENT to the Loan and Security Agreement dated as of June 15, 2023 among BEYOND AIR, INC. (“Borrower”) and AVENUE CAPITAL MANAGEMENT II, L.P., a Delaware limited partnership, as administrative agent and collateral agent (in such capacity “Agent”) and AVENUE VENTURE OPPORTUNITIES FUND, L.P., a Delaware limited partnership (“Avenue”), as a lender and AVENUE VENTURE OPPORTUNITIES FU

Beyond Air® Secures up to $40 Million Debt Financing Funding to support the commercialization of LungFit® PH and advance the clinical development of high concentration nitric oxide treatment using Beyond Air’s revolutionary LungFit platform technolog

Exhibit 99.1 Beyond Air® Secures up to $40 Million Debt Financing Funding to support the commercialization of LungFit® PH and advance the clinical development of high concentration nitric oxide treatment using Beyond Air’s revolutionary LungFit platform technology GARDEN CITY, N.Y., June 15, 2023 – Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device a

Warrant to Purchase Common Stock, by and between Beyond Air, Inc. and Avenue Venture Opportunities Fund, L.P., dated as of June 15, 2023, filed as Exhibit 4.1 to our Current Report on Form 8-K, as filed with the SEC on June 20, 2023, and incorporated herein by reference.

Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR

Loan and Security Agreement, by and among Beyond Air, Inc., Beyond Air Ltd., Avenue Capital Management II, L.P., as Agent, and the Lenders party thereto, dated as of June 15, 2023, filed as Exhibit 10.1 to our Current Report on Form 8-K, as filed with the SEC on June 20, 2023 and incorporated herein by reference.

Exhibit 10.1 LOAN AND SECURITY AGREEMENT Dated as of June 15, 2023 among BEYOND AIR, INC., a Delaware corporation, as “Borrower”, BEYOND AIR LTD., an Israeli private company, company # 514609387 as a “Israeli Guarantor” or “Beyond Israel” and AVENUE CAPITAL MANAGEMENT II, L.P., a Delaware limited partnership (as administrative agent and collateral agent (in such capacity “Agent”) and AVENUE VENTUR

Warrant to Purchase Common Stock, by and between Beyond Air, Inc. and Avenue Venture Opportunities Fund II, L.P., dated as of June 15, 2023, filed as Exhibit 4.2 to our Current Report on Form 8-K, as filed with the SEC on June 20, 2023, and incorporated herein by reference.

Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 15, 2023 Beyond Air, Inc. (E

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 15, 2023 Beyond Air, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38892 47-3812456 (State or Other Jurisdiction of Incorporation) (Commission File Number)

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 23, 2023 Beyond Air, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38892 47-3812456 (State or Other Jurisdiction of Incorporation) (Commission File Number

Beyond Air® Appoints Jeff Myers, M.D. Ph.D. as Chief Medical Officer Dr. Myers brings extensive executive experience leading the development of clinical programs through US and global regulatory approval

Exhibit 99.1 Beyond Air® Appoints Jeff Myers, M.D. Ph.D. as Chief Medical Officer Dr. Myers brings extensive executive experience leading the development of clinical programs through US and global regulatory approval Garden City, NY, March 23, 2023 – Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on developin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 23, 2023 Beyond Air, Inc. (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 23, 2023 Beyond Air, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38892 47-3812456 (State or Other Jurisdiction of Incorporation) (Commission File Number

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 9, 2023 Beyond Air, Inc. (E

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 9, 2023 Beyond Air, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38892 47-3812456 (State or Other Jurisdiction of Incorporation) (Commission File Number)

Filing Fee Table.

Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Beyond Air, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Proposed Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, par value

As filed with the Securities and Exchange Commission on February 17, 2023

As filed with the Securities and Exchange Commission on February 17, 2023 Registration No.

Form of Stock Option Agreement (Inducement Grant).

Exhibit 10.2 Stock Option Inducement Agreement This Stock Option Inducement Agreement (this “Agreement”) is made and entered into as of [DATE] by and between BEYOND AIR, INC., a Delaware corporation (the “Company”) and [NAME] (the “Participant”). Grant Date: Exercise Price per Share: Number of Option Shares: Expiration Date: 1. Grant of Option. 1.1 Grant; Type of Option. The Company desires to emp

XAIR / Beyond Air Inc / Mosseri Marlio Charles - SC 13G/A Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 Beyond Air, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 08862L103 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule

Beyond Air® Reports Financial Results for the Third Quarter of Fiscal Year 2023 U.S. commercial launch continues for LungFit® PH for the treatment of term and near-term neonates with hypoxic respiratory failure Presented positive in vivo combination

Exhibit 99.1 Beyond Air® Reports Financial Results for the Third Quarter of Fiscal Year 2023 U.S. commercial launch continues for LungFit® PH for the treatment of term and near-term neonates with hypoxic respiratory failure Presented positive in vivo combination data with anti-PD1 that support the potential of the Company’s novel gaseous ultra-high concentration nitric oxide (UNO) therapy to treat

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 9, 2023 Beyond Air, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 9, 2023 Beyond Air, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38892 47-3812456 (State or Other Jurisdiction of Incorporation) (Commission File Numb

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38892 BEYOND AIR, INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State

Beyond Air® Reports Financial Results for the Second Quarter of Fiscal Year 2023 Commercial launch underway for LungFit® PH for the treatment of term and near-term neonates with hypoxic respiratory failure, which received FDA approval on June 28, 202

Exhibit 99.1 Beyond Air? Reports Financial Results for the Second Quarter of Fiscal Year 2023 Commercial launch underway for LungFit? PH for the treatment of term and near-term neonates with hypoxic respiratory failure, which received FDA approval on June 28, 2022 Presented favorable safety, tolerability, and efficacy results from the pilot study of at-home LungFit? GO for nontuberculous mycobacte

Beyond Cancer™ Presents Promising New In Vivo Data Showing Ultra-High Concentration Nitric Oxide Therapy (UNO) in Combination with Anti-PD-1 During the Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting Data showing UNO in combination wit

Exhibit 99.2 Beyond Cancer? Presents Promising New In Vivo Data Showing Ultra-High Concentration Nitric Oxide Therapy (UNO) in Combination with Anti-PD-1 During the Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting Data showing UNO in combination with anti-PD-1 treatment leads to significantly higher tumor regression rates UNO in combination with anti-PD-1 treatment results in a highe

Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 8, 2022 Beyond Air, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38892 47-3812456 (State or Other Jurisdiction of Incorporation) (Commission File Numb

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 ☐ TRANSITION REPORT PURSUANT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38892 BEYOND AIR, INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 20, 2022 Beyond Air, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 20, 2022 Beyond Air, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38892 47-3812456 (State or Other Jurisdiction of Incorporation) (Commission File Numb

Beyond Air® Announces Positive Data from At-Home Pilot Study in Patients with Refractory NTM Lung Infection Treated with (NO) using the LungFit® GO at the CHEST Annual Meeting 2022 — Data show favorable safety, tolerability, and efficacy results — —

Exhibit 99.1 Beyond Air? Announces Positive Data from At-Home Pilot Study in Patients with Refractory NTM Lung Infection Treated with (NO) using the LungFit? GO at the CHEST Annual Meeting 2022 ? Data show favorable safety, tolerability, and efficacy results ? ? All patients titrated to 250 ppm NO with no patients needing to reduce concentration ? ? All patients demonstrated ability to self-admini

Letter from Friedman LLP to the Securities and Exchange Commission, dated October 6, 2022

Exhibit 16.1 October 6, 2022 Securities and Exchange Commission 100 F Street, NE Washington, D.C. 20549 Re: Beyond Air, Inc. Commission File Number 001-38892 Commissioners: We have read the statements made by Beyond Air, Inc. under Item 4.01 of its Form 8-K dated October 6, 2022. We agree with the statements concerning our firm in such Form 8-K; we are not in a position to agree or disagree with o

Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 6, 2022 Beyond Air, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38892 47-3812456 (State or Other Jurisdiction of Incorporation) (Commission File Numbe

Other Events, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 23, 2022 Beyond Air, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38892 47-3812456 (State or Other Jurisdiction of Incorporation) (Commission File Numbe

Beyond Air® Affiliate Beyond Cancer™ Doses Initial Patient in First-in-Human Phase 1 Study of Ultra- High Concentration Nitric Oxide Therapy at Tel Aviv Sourasky Medical Center (Ichilov)

Exhibit 99.1 Beyond Air? Affiliate Beyond Cancer? Doses Initial Patient in First-in-Human Phase 1 Study of Ultra- High Concentration Nitric Oxide Therapy at Tel Aviv Sourasky Medical Center (Ichilov) GARDEN CITY, N.Y. and HAMILTON, Bermuda, Aug. 23, 2022 ? Beyond Cancer, Ltd., an affiliate of Beyond Air, Inc. (NASDAQ: XAIR) that is focused on developing ultra-high concentration nitric oxide (UNO)

Beyond Air® Reports Financial Results for the First Quarter of Fiscal Year 2023 Initiated U.S. commercial launch of LungFit® PH for the treatment of term and near-term neonates with hypoxic respiratory failure, which received FDA approval on June 28,

Exhibit 99.1 Beyond Air? Reports Financial Results for the First Quarter of Fiscal Year 2023 Initiated U.S. commercial launch of LungFit? PH for the treatment of term and near-term neonates with hypoxic respiratory failure, which received FDA approval on June 28, 2022 Will present data from the pilot study of at-home LungFit? GO for nontuberculous mycobacterial lung infection at the American Colle

Results of Operations and Financial Condition, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 11, 2022 Beyond Air, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38892 47-3812456 (State or Other Jurisdiction of Incorporation) (Commission File Numbe

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 ☐ TRANSITION REPORT PURSUANT TO S

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38892 BEYOND AIR, INC. (Exa

Employment Agreement, dated as of April 24, 2020, by and between Beyond Air, Inc. and Michael Gaul, filed as Exhibit 10.1 to our Current Report on Form 8-K, filed with the SEC on July 5, 2022 and incorporated herein by reference.

Exhibit 10.1 April 24, 2020 via email Michael Gaul 4975 E. Lake Road Sheffield Lake, OH 44054 Re: Employment as Senior VP, Operations Dear Mr. Gaul: We are pleased to offer you a position as Senior VP, Operations on the terms set forth below. 1. Job title Your title will be Senior VP, Operations and you will report to Steve Lisi. The reporting structure may change from time to time, at the discret

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 28, 2022 Beyond Air, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38892 47-3812456 (State or Other Jurisdiction of Incorporation) (Commission File Number)

Beyond Air’s LungFit® PH Receives FDA Approval to Treat Term and Near-Term Neonates with Hypoxic Respiratory Failure First and only nitric oxide generator and delivery system indicated for the treatment of term and near-term neonates with hypoxic res

Exhibit 99.2 Beyond Air?s LungFit? PH Receives FDA Approval to Treat Term and Near-Term Neonates with Hypoxic Respiratory Failure First and only nitric oxide generator and delivery system indicated for the treatment of term and near-term neonates with hypoxic respiratory failure that uses ambient air to provide unlimited, on-demand nitric oxide Eliminates the need for traditional nitric oxide tank

Other Events, Results of Operations and Financial Condition, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 28, 2022 Beyond Air, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38892 47-3812456 (State or Other Jurisdiction of Incorporation) (Commission File Number)

Beyond Air® Reports Financial Results for Fourth Fiscal Quarter and Year-End 2022 LungFit® PH received FDA approval for the treatment of term and near-term neonates with hypoxic respiratory failure on June 28, 2022 and the first phase of U.S. commerc

Exhibit 99.1 Beyond Air? Reports Financial Results for Fourth Fiscal Quarter and Year-End 2022 LungFit? PH received FDA approval for the treatment of term and near-term neonates with hypoxic respiratory failure on June 28, 2022 and the first phase of U.S. commercial launch has begun Presented positive data for high-concentration nitric oxide (NO) with LungFit? PRO in hospitalized patients with com

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED MARCH 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-38892 BEYOND AIR, INC.

List of subsidiaries of Beyond Air, Inc.

Exhibit 21.1 Subsidiary Jurisdiction of Incorporation Beyond Air Ltd. Israel Beyond Air Ireland Limited Ireland Beyond Air Australia Pty. Ltd. Australia Beyond Cancer Bermuda Limited Bermuda Beyond Cancer U.S., Inc. Delaware XAIR Israel Ltd Israel Beyond Cancer Cyprus Limited Cyprus

Financial Statements and Exhibits, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 3, 2022 Beyond Air, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38892 47-3812456 (State or Other Jurisdiction of Incorporation) (Commission File Number)

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 10, 2022 Beyond Air, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38892 47-3812456 (State or Other Jurisdiction of Incorporation) (Commission File Num

Beyond Air® Reports Financial Results for the Third Quarter of Fiscal Year 2022 LungFit® PH premarket approval (PMA) submission under active review by U.S. FDA; approval and commercial launch anticipated in the first half of calendar year 2022 along

Exhibit 99.1 Beyond Air? Reports Financial Results for the Third Quarter of Fiscal Year 2022 LungFit? PH premarket approval (PMA) submission under active review by U.S. FDA; approval and commercial launch anticipated in the first half of calendar year 2022 along with European CE Mark Raised $30 million for oncology affiliate Beyond Cancer?, Beyond Air maintained an 80% equity ownership; first in h

XAIR / Beyond Air Inc / Flynn James E Passive Investment

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2021 ☐ TRANSITION REPORT PURSUANT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38892 BEYOND AIR, INC.

XAIR / Beyond Air Inc / Mosseri Marlio Charles - SC 13G/A Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Amendment No. 2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Beyond Air, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 08862L103 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule p

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 4, 2022 Beyond Air, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38892 47-3812456 (State or other jurisdiction of incorporation) (Commission File

Beyond Air, Inc. Common Stock

Filed Pursuant to Rule 424(b)(5) Registration No. 333-262311 PROSPECTUS SUPPLEMENT (To Prospectus dated February 1, 2022) $50,000,000 Beyond Air, Inc. Common Stock We have entered into a sales agreement with Truist Securities, Inc., or Truist, and Oppenheimer & Co. Inc., or Oppenheimer, each of whom we refer to as an agent, and together as the agents, relating to shares of our common stock offered

At-The-Market Equity Offering Sales Agreement, dated as of February 4, 2022, by and among Beyond Air, Inc., Truist Securities, Inc., and Oppenheimer & Co. Inc., filed as Exhibit 1.1 to our Current Report on Form 8-K, as filed with the SEC on February 4, 2022 and incorporated herein by reference.

Exhibit 1.1 Beyond Air, Inc. $50,000,000 COMMON STOCK SALES AGREEMENT February 4, 2022 Truist Securities, Inc. 3333 Peachtree Road, 11th Floor Atlanta, Georgia 30326 Oppenheimer & Co. Inc. 85 Broad Street New York, New York 10004 Ladies and Gentlemen: Beyond Air, Inc., a Delaware corporation (the ?Company?), Truist Securities, Inc. (?Truist?), as sales agent, and Oppenheimer & Co. Inc. (?Oppenheim

Beyond Air, Inc. 900 Stewart Avenue, Suite 301 Garden City, NY 11530 January 28, 2022

Beyond Air, Inc. 900 Stewart Avenue, Suite 301 Garden City, NY 11530 January 28, 2022 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Beyond Air, Inc. Registration Statement on Form S-3 Filed January 24, 2022 File No. 333-262311 Request for Acceleration of Effective Date Ladies and Gentlemen: Pursuant to Rule 461 of th

Form of Indenture (filed herewith).

Exhibit 4.8 BEYOND AIR, INC. and as Trustee INDENTURE Dated as of , ARTICLE 1 DEFINITIONS AND INCORPORATION BY REFERENCE 1 1.1 Definitions 1 1.2 Other Definitions 5 1.3 Incorporation by Reference of Trust Indenture Act 5 1.4 Rules of Construction 6 ARTICLE 2 THE SECURITIES 6 2.1 Issuable in Series 6 2.2 Establishment of Terms of Series of Securities 7 2.3 Execution and Authentication 9 2.4 Registr

As filed with the Securities and Exchange Commission on January 24, 2022

As filed with the Securities and Exchange Commission on January 24, 2022 Registration No.

Beyond Air, Inc. Fourth Amended and Restated 2013 Equity Incentive Plan (included in Appendix A to our Definitive Proxy Statement filed on January 21, 2022 and incorporated herein by reference).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State

Beyond Air® Provides Regulatory Update for LungFit® PH

Exhibit 99.1 Beyond Air? Provides Regulatory Update for LungFit? PH GARDEN CITY, N.Y., Dec. 09, 2021 (GLOBE NEWSWIRE) ? Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and, through its

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 9, 2021 Beyond Air, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38892 47-3812456 (State or Other Jurisdiction of Incorporation) (Commission File Numb

Beyond Air® Reports Financial Results for the Second Quarter of Fiscal Year 2022 U.S. FDA actively reviewing premarket approval (PMA) submission for LungFit® PH to treat persistent pulmonary hypertension of the newborn (PPHN); Remain on track for com

Exhibit 99.1 Beyond Air? Reports Financial Results for the Second Quarter of Fiscal Year 2022 U.S. FDA actively reviewing premarket approval (PMA) submission for LungFit? PH to treat persistent pulmonary hypertension of the newborn (PPHN); Remain on track for commercial launch in the fourth quarter of calendar year 2021 Raised $23.9 million to form a new private, independently managed entity, call

Termination of a Material Definitive Agreement, Results of Operations and Financial Condition, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 10, 2021 Beyond Air, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38892 47-3812456 (State or Other Jurisdiction of Incorporation) (Commission File Num

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 ☐ TRANSITION REPORT PURSUANT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38892 BEYOND AIR, INC.

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 4, 2021 Beyond Air, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38892 47-3812456 (State or Other Jurisdiction of Incorporation) (Commission File Numb

Beyond Air® Announces Formation of Beyond Cancer™, a New Private Company Dedicated to Oncology Utilizing Ultra-High Concentration Nitric Oxide to Treat Solid Tumors $23.9 million committed in concurrent equity private placement to form Beyond Cancer

Exhibit 99.1 Beyond Air? Announces Formation of Beyond Cancer?, a New Private Company Dedicated to Oncology Utilizing Ultra-High Concentration Nitric Oxide to Treat Solid Tumors $23.9 million committed in concurrent equity private placement to form Beyond Cancer that will leverage Beyond Air?s nitric oxide (NO) expertise and take over development of current solid tumor pipeline Beyond Cancer is le

Other Events, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 14, 2021 Beyond Air, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38892 47-3812456 (State or Other Jurisdiction of Incorporation) (Commission File Numb

Beyond Air® Reports Positive Interim Results for LungFit® GO Pilot Study Using High Concentration Inhaled Nitric Oxide Self-Administered, At-Home for Nontuberculous Mycobacterial Lung Disease Interim results show that 250 parts per million (ppm) nitr

Exhibit 99.1 Beyond Air? Reports Positive Interim Results for LungFit? GO Pilot Study Using High Concentration Inhaled Nitric Oxide Self-Administered, At-Home for Nontuberculous Mycobacterial Lung Disease Interim results show that 250 parts per million (ppm) nitric oxide (NO) was well-tolerated with no study discontinuations or treatment-related serious adverse events observed At the time of data

Beyond Air® Provides Global Regulatory Update for LungFit® PH FDA inspection of facilities is ongoing; US commercial launch remains on track for 4Q CY2021, pending FDA approval Stage 1 Assessment Audit in the CE Mark process is complete; expect to re

Exhibit 99.1 Beyond Air? Provides Global Regulatory Update for LungFit? PH FDA inspection of facilities is ongoing; US commercial launch remains on track for 4Q CY2021, pending FDA approval Stage 1 Assessment Audit in the CE Mark process is complete; expect to receive CE Mark in 1H CY2022 GARDEN CITY, N.Y., Sept. 21, 2021 (GLOBE NEWSWIRE) ? Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical

Other Events, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 21, 2021 Beyond Air, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38892 47-3812456 (State or Other Jurisdiction of Incorporation) (Commission File Nu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 20, 2021 Beyond Air, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 20, 2021 Beyond Air, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38892 47-3812456 (State or Other Jurisdiction of Incorporation) (Commission File Numbe

Employment Agreement, dated as of August 20, 2021, by and between Beyond Air, Inc. and Douglas Larson, filed as Exhibit 10.1 to our Current Report on Form 8-K, filed with the SEC on August 25, 2021 and incorporated herein by reference.

Exhibit 10.1 EMPLOYMENT AGREEMENT EMPLOYMENT AGREEMENT is effective on August 20th, 2021 between Beyond Air, Inc. (the ?Company?), a Delaware corporation, and Douglas Larson (the ?Employee?). Recital: The parties desire to enter into this Agreement so as to provide for the employment of the Employee by the Company and for certain other matters in connection with such employment, all as set forth m

Beyond Air® Announces CFO Transition

Exhibit 99.1 Beyond Air? Announces CFO Transition GARDEN CITY, N.Y., August 20, 2021 (GLOBE NEWSWIRE) ? Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and gaseous NO (gNO) for the tre

Consulting and Severance Agreement, dated August 24, 2021, by and between Douglas Beck and Beyond Air, Inc.

Exhibit 10.2 CONSULTING AND SEVERANCE AGREEMENT This CONSULTING AND SEVERANCE AGREEMENT (this ?Agreement?) is made and entered into by and between BEYOND AIR, INC., a Delaware corporation (the ?Company?) and Douglas Beck (the ?Beck? and together with the Company, the ?Parties?) on August 18, 2021. WHEREAS, until August 31, 2021, Beck served as Chief Financial Officer (?CFO?) under the terms set fo

Beyond Air® Reports Financial Results for the First Quarter of Fiscal Year 2022 U.S. FDA reviewing premarket approval (PMA) submission for LungFit® PH to treat persistent pulmonary hypertension of the newborn (PPHN); On track for commercial launch in

Exhibit 99.1 Beyond Air? Reports Financial Results for the First Quarter of Fiscal Year 2022 U.S. FDA reviewing premarket approval (PMA) submission for LungFit? PH to treat persistent pulmonary hypertension of the newborn (PPHN); On track for commercial launch in the fourth quarter of calendar year 2021 Anticipate reporting interim results from the LungFit? GO Nontuberculous Mycobacteria (NTM) lun

Results of Operations and Financial Condition, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 10, 2021 Beyond Air, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38892 47-3812456 (State or Other Jurisdiction of Incorporation) (Commission File Numbe

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 ☐ TRANSITION REPORT PURSUANT TO S

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38892 BEYOND AIR, INC. (Exa

Executive Employment Agreement, dated as of June 30, 2018, by and between AIT Therapeutics Inc. and Steven Lisi, filed as Exhibit 10.2 to our Quarterly Report on Form 10-Q, as filed with the SEC on August 10, 2021 and incorporated herein by reference.

Exhibit 10.2 AIT THERAPEUTICS INC. EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (?Agreement?) is made and entered into as of June 30, 2018, by and between AIT THERAPEUTICS INC., a Delaware corporation (?Employer?), and Steven Lisi (?Executive?). 1. Employment. Employer employs Executive, and Executive accepts employment with Employer, on the terms and conditions set forth in

Settlement Agreement and Release, dated May 26, 2021, by and between Beyond Air, Inc. and Circassia Limited, filed as Exhibit 10.1 to our Quarterly Report on Form 10-Q, as filed with the SEC on August 10, 2021 and incorporated herein by reference.

Exhibit 10.1 CERTAIN INFORMATION IN THIS DOCUMENT, MARKED BY [***], HAS BEEN EXCLUDED PURSUANT TO REGULATION S-K, ITEM 601(b)(10)(iv). SUCH EXCLUDED INFORMATION IS NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. SETTLEMENT AGREEMENT AND RELEASE This Settlement Agreement and Release (this ?Settlement Agreement?), is entered into by and between BEYOND AIR, INC., f

Executive Employment Agreement, dated June 30, 2018, by and between AIT Therapeutics, Inc. and Amir Avniel.

Exhibit 10.3 AIT THERAPEUTICS INC. EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (?Agreement?) is made and entered into as of June 30, 2018, by and between AIT THERAPEUTICS INC., a Delaware corporation (?Employer?), and Amir Avniel (?Executive?). 1. Employment. Employer employs Executive, and Executive accepts employment with Employer, on the terms and conditions set forth in

List of subsidiaries of Beyond Air, Inc.

Exhibit 21.1 Subsidiary Jurisdiction of Incorporation Beyond Air Ltd. Israel Advanced Inhalation Therapies Inc. Delaware Beyond Air Ireland Limited Ireland Beyond Air Australia Pty. Ltd. Australia

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K/A Amendment No.1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K/A Amendment No.

As filed with the Securities and Exchange Commission on June 30, 2021

As filed with the Securities and Exchange Commission on June 30, 2021 Registration No.

Results of Operations and Financial Condition, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 10, 2021 Beyond Air, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38892 47-3812456 (State or Other Jurisdiction of Incorporation) (Commission File Number)

Beyond Air® Reports Financial Results for Fourth Fiscal Quarter and Year-End 2021 Submitted first premarket approval (PMA) application in the Company’s history to FDA for LungFit® PH to treat persistent pulmonary hypertension of the newborn (PPHN); C

Exhibit 99.1 Beyond Air? Reports Financial Results for Fourth Fiscal Quarter and Year-End 2021 Submitted first premarket approval (PMA) application in the Company?s history to FDA for LungFit? PH to treat persistent pulmonary hypertension of the newborn (PPHN); Company preparing for commercial launch in the fourth quarter of calendar year 2021 Expanded the commercial and business development teams

List of subsidiaries of Beyond Air, Inc.

Exhibit 21.1 Subsidiary Jurisdiction of Incorporation Beyond Air Ltd. Israel Beyond Air Ireland Limited Ireland Beyond Air Australia Pty. Ltd. Australia

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED MARCH 31, 2021 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-38892 BEYOND AIR, INC.

Entry into a Material Definitive Agreement

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 26, 2021 Beyond Air, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38892 47-3812456 (State or Other Jurisdiction of Incorporation) (Commission File Number)

Other Events, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 13, 2021 Beyond Air, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38892 47-3812456 (State or Other Jurisdiction of Incorporation) (Commission File Number)

Beyond Air® Presents Data in Hospitalized Patients with Viral Lung Infections (including COVID-19) from LungFit® PRO Programs at ATS 2021 Interim analysis from the ongoing, open-label, randomized acute viral pneumonia (including COVID-19) pilot study

Exhibit 99.1 Beyond Air? Presents Data in Hospitalized Patients with Viral Lung Infections (including COVID-19) from LungFit? PRO Programs at ATS 2021 Interim analysis from the ongoing, open-label, randomized acute viral pneumonia (including COVID-19) pilot study shows 150 ppm nitric oxide (NO) administered with LungFit? PRO is well-tolerated with no treatment-related adverse events, and demonstra

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A UNDER THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A UNDER THE SECURITIES EXCHANGE ACT OF 1934 Beyond Air, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 08862L103 (CUSIP Number) April 30, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which th

Financial Statements and Exhibits, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 4, 2021 Beyond Air, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38892 47-3812456 (State or Other Jurisdiction of Incorporation) (Commission File Number)

Beyond Air, Inc. 2021 Employee Stock Purchase Plan, filed as Exhibit 10.2 to our Current Report on Form 8-K, as filed with the SEC on March 9, 2021 and incorporated herein by reference.

Exhibit 10.2 beyond air, inc. 2021 EMPLOYEE STOCK PURCHASE PLAN Beyond air, inc. 2021 Employee Stock Purchase Plan 1. Purpose and Interpretation (a) The purpose of the Plan is to encourage and to enable Eligible Employees of the Company and its Participating Affiliates, through after-tax payroll deductions, to acquire proprietary interests in the Company through the purchase and ownership of share

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 16, 2021 Beyond Air, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-38892 47-3812456 (State or Other Jurisdiction of Incorporation) (Commission File Num

Beyond Air® Receives Grant for Up to $2.17 million from the Cystic Fibrosis Foundation to Advance the Clinical Development of Inhaled Nitric Oxide to Treat Nontuberculous Mycobacteria Pulmonary Disease Award will help fund the development of high con

Exhibit 99.1 Beyond Air? Receives Grant for Up to $2.17 million from the Cystic Fibrosis Foundation to Advance the Clinical Development of Inhaled Nitric Oxide to Treat Nontuberculous Mycobacteria Pulmonary Disease Award will help fund the development of high concentration nitric oxide (NO) for Nontuberculous Mycobacteria (NTM) pulmonary disease, which disproportionately affects cystic fibrosis (C

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION STATEMENT TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b) (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 (b) (Amendment N

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION STATEMENT TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b) (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 (b) (Amendment No. 2)* Beyond Air, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 08862L103 (CUSIP Number) December 31, 2020 (Date of Event Which R

Results of Operations and Financial Condition, Financial Statements and Exhibits -

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 9, 2021 Beyond Air, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-38892 47-3812456 (State or Other Jurisdiction of Incorporation) (Commission File Numb

Beyond Air® Reports Financial Results for Third Quarter of Fiscal Year 2021 and Provides Business Update U.S. FDA reviewing premarket approval (PMA) submission for LungFitTM PH to treat persistent pulmonary hypertension of the newborn (PPHN), as Comp

Exhibit 99.1 Beyond Air® Reports Financial Results for Third Quarter of Fiscal Year 2021 and Provides Business Update U.S. FDA reviewing premarket approval (PMA) submission for LungFitTM PH to treat persistent pulmonary hypertension of the newborn (PPHN), as Company prepares for commercialization Interim results from the acute viral pneumonia (including SARS-CoV-2) pilot study using 150 ppm nitric

Quarterly Report -

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2020 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38892 BEYOND AIR, I

-

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) [ ] Definitive P

Form of Second Certificate of Amendment of the Amended and Restated Certificate of Incorporation of Beyond Air, Inc. (included in Appendix C to our Definitive Proxy Statement, filed with the SEC on January 22, 2021 and incorporated herein by reference).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) [X] Definitive P

-

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1) Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [X] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)

-

Hogan Lovells US LLP 1735 Market Street, Floor 23 Philadelphia, PA 19103 T +1 267 675 4600 F +1 267 675 4601 www.

-

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [X] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) [ ] Definitive P

Other Events, Financial Statements and Exhibits -

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 7, 2020 Beyond Air, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 000-38892 47-3812456 (State or Other Jurisdiction of Incorporation) (Commission File

Expect to dose first patient in January 2021 and report interim data mid-2021 Success in nontuberculous mycobacteria (NTM) at-home study paves the way to enter the much broader market treating severe lung infections in the home

Exhibit 99.1 Beyond Air® Initiates Patient Screening for LungFit™ GO Pilot Study for At-Home, Self-Administration of Inhaled Nitric Oxide in Nontuberculous Mycobacteria Lung Disease Expect to dose first patient in January 2021 and report interim data mid-2021 Success in nontuberculous mycobacteria (NTM) at-home study paves the way to enter the much broader market treating severe lung infections in

Regulation FD Disclosure, Financial Statements and Exhibits -

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2020 Beyond Air, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-38892 47-3812456 (State or Other Jurisdiction of Incorporation) (Commission File

Corporate Presentation of Beyond Air, Inc.

Exhibit 99.1

Quarterly Report -

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38892 BEYOND AIR,

Other Events, Financial Statements and Exhibits

8-K 1 form8-k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 11, 2020 Beyond Air, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 000-38892 47-3812456 (State or Other Jurisdiction of Incorporation

Potential to revolutionize nitric oxide therapy by eliminating need for cumbersome cylinders creating improved economics and safety in hospital setting Will be subject to a 180-day review period by the FDA Launch expected in 2Q 2021, pending approval

Exhibit 99.1 Beyond Air? Submits Premarket Approval Application to FDA for LungFit? PH to Treat Persistent Pulmonary Hypertension of the Newborn Potential to revolutionize nitric oxide therapy by eliminating need for cumbersome cylinders creating improved economics and safety in hospital setting Will be subject to a 180-day review period by the FDA Launch expected in 2Q 2021, pending approval GARD

Regulation FD Disclosure, Financial Statements and Exhibits -

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 1, 2020 Beyond Air, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-38892 47-3812456 (State or Other Jurisdiction of Incorporation) (Commission File

Corporate Presentation of Beyond Air, Inc.

Exhibit 99.1

Manufacture and Supply Agreement, dated as of July 30, 2020, by and between Beyond Air, Inc. and Medisize Ireland Limited, filed as Exhibit 10.1 to our Current Report on Form 8-K, as filed with the SEC on August 18, 2020 and incorporated herein by reference.

Exhibit 10.1 [***] Certain identified information, marked by brackets, has been excluded from the exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. MASTER AGREEMENT MANUFACTURE AND SUPPLY AGREEMENT For Medical Products This MANUFACTURING AGREEMENT (“Agreement”) is entered into as of August 6, 2020 2020 (“Effective Date”) between Beyond Air,

Entry into a Material Definitive Agreement, Financial Statements and Exhibits -

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 18, 2020 (August 12, 2020) Beyond Air, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-38892 47-3812456 (State or Other Jurisdiction of Incorporation)

Supply Agreement, dated as of August 6, 2020, by and between Beyond Air, Inc. and Spartronics Watertown, LLC, filed as Exhibit 10.1 to our Current Report on Form 8-K, as filed with the SEC on August 12, 2020 and incorporated herein by reference.

Exhibit 10.1 [***] Certain identified information, marked by brackets, has been excluded from the exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. DATED July 30, 2020 BEYOND AIR, INC. AND spartronics watertown, llc SUPPLY AGREEMENT CONTENTS 1. Definitions 1 2. Appointment and Term 6 3. PRODUCT MANAGEMENT, Forecasting and Orders 6 4. Manufac

Regulation FD Disclosure, Results of Operations and Financial Condition, Entry into a Material Definitive Agreement, Financial Statements and Exhibits -

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2020 (August 6, 2020) Beyond Air, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-38892 47-3812456 (State or Other Jurisdiction of Incorporation) (

U.S. COVID-19 study showing positive safety profile for patients enrolled to date PMA for LungFitTM PH to treat persistent pulmonary hypertension of the newborn (PPHN) expected to be submitted to the FDA at the end of September 2020 LungFitTM HOME no

Exhibit 99.1 Beyond Air® Reports Financial Results for First Quarter of Fiscal Year 2021 and Provides Business Update U.S. COVID-19 study showing positive safety profile for patients enrolled to date PMA for LungFitTM PH to treat persistent pulmonary hypertension of the newborn (PPHN) expected to be submitted to the FDA at the end of September 2020 LungFitTM HOME nontuberculous mycobacteria (NTM)

Quarterly Report -

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38892 BEYOND AIR, INC.

Corporate Presentation of Beyond Air, Inc.

Exhibit 99.1

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 1, 2020 Beyond Air, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-38892 47-3812456 (State or Other Jurisdiction of Incorporation) (Commission File Numb

List of subsidiaries of Beyond Air, Inc.

EX-21.1 3 ex21-1.htm Exhibit 21.1 Subsidiary Jurisdiction of Incorporation Beyond Air Ltd. Israel Advanced Inhalation Therapies Inc. Delaware Beyond Air Ireland Limited Ireland Beyond Air Australia Pty. Ltd. Australia

Regulation FD Disclosure, Results of Operations and Financial Condition, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 22, 2020 Beyond Air, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-38892 47-3812456 (State or Other Jurisdiction of Incorporation) (Commission File Num

Exhibit 4.7

Exhibit 4.7 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES ACT OF 1934 The following description sets forth certain material terms and provisions of our securities that are registered under Section 12 of the Securities Exchange Act of 1934, as amended. Common Stock The holders of our common stock are entitled to one vote per share on all matters subm

Beyond Air Reports Financial Results for Fiscal Fourth Quarter and Year-End 2020

EX-99.1 2 ex99-1.htm Exhibit 99.1 Beyond Air Reports Financial Results for Fiscal Fourth Quarter and Year-End 2020 Reported positive clinical data for third bronchiolitis study using high concentration nitric oxide, achieving primary and key secondary endpoints Enrolled first patient in the U.S. COVID-19 study using the LungFit™ system Announced positive pre-clinical data validating high concentra

Annual Report -

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED MARCH 31, 2020 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-38892 BEYOND AIR, INC.

Other Events, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 22, 2020 Beyond Air, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-38892 47-3812456 (State or Other Jurisdiction of Incorporation) (Commission File Num

Beyond Air Announces Positive Preclinical Data Supporting High Concentration Nitric Oxide as a Potential Treatment for Solid Tumors

Exhibit 99.1 Beyond Air Announces Positive Preclinical Data Supporting High Concentration Nitric Oxide as a Potential Treatment for Solid Tumors Globenewswire June 22, 2020 Data demonstrate the ablation of solid tumors with nitric oxide All tumor-bearing mice treated with nitric oxide rejected a second tumor challenge, suggesting induction of an anti-tumor immune response GARDEN CITY, N.Y., June 2

Other Events, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 26, 2020 Beyond Air, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-38892 47-3812456 (State or Other Jurisdiction of Incorporation) (Commission File Numb

Beyond Air Receives Approval from Health Canada to Study Nitric Oxide Generated and Delivered by the LungFit™ in COVID-19 Patients Anticipate study start in June 2020

Exhibit 99.1 Beyond Air Receives Approval from Health Canada to Study Nitric Oxide Generated and Delivered by the LungFit™ in COVID-19 Patients Anticipate study start in June 2020 Garden City, NY, May 26, 2020 – Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with respirator

Other Events, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 20, 2020 Beyond Air, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-38892 47-3812456 (State or Other Jurisdiction of Incorporation) (Commission File Numb

Beyond Air Achieves Primary Endpoint in Pilot Bronchiolitis Study High concentration nitric oxide (150 ppm) is statistically significant compared to both low concentration nitric oxide (85 ppm) and control arms on both the primary endpoint and the ke

Exhibit 99.1 Beyond Air Achieves Primary Endpoint in Pilot Bronchiolitis Study High concentration nitric oxide (150 ppm) is statistically significant compared to both low concentration nitric oxide (85 ppm) and control arms on both the primary endpoint and the key secondary endpoint No serious adverse events related to NO therapy Third consecutive successful pilot study in bronchiolitis Garden Cit